Clifton Park, NY, United States of America

Lawrence G Stoll

This inventor holds 3 USPTO granted patents and 4 published patent applications. Top assignees: Pedicis Research LLC, Other. Active years: 2020-2023.

USPTO Granted Patents = 3 

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2020-2023

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Lawrence G Stoll

Introduction

Lawrence G Stoll is a notable inventor based in Clifton Park, NY (US). He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of skin infections. With a total of 3 patents to his name, Stoll's work reflects a commitment to advancing medical treatments.

Latest Patents

Stoll's latest patents focus on compositions and methods for the treatment of skin infections. One of his key inventions describes a pharmaceutical composition that may include a combination of a pharmaceutically acceptable excipient, a keratolytic, ethyl pyruvate, and povidone iodine. The method involves the topical application of this composition to infected skin cells for an effective treatment period. This innovative approach aims to enhance the efficacy of skin infection treatments.

Career Highlights

Throughout his career, Stoll has worked with various companies, including Pedicis Research LLC. His experience in the pharmaceutical industry has allowed him to develop and refine his inventions, contributing to advancements in medical science.

Collaborations

Stoll has collaborated with professionals in his field, including Robert Alonso. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work.

Conclusion

Lawrence G Stoll's contributions to the treatment of skin infections through his innovative patents demonstrate his dedication to improving healthcare solutions. His work continues to influence the pharmaceutical industry and offers hope for more effective treatments in the future.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…